Dosage-dependent Regulation of Cell Proliferation and Adhesion Through Dual β2-adrenergic Receptor/cAMP Signals
Overview
Affiliations
The role of β-adrenergic receptors (β-ARs) remains controversial in normal and tumor breast. Herein we explore the cAMP signaling involved in β-AR-dependent control of proliferation and adhesion of nontumor human breast cell line MCF-10A. Low concentrations of a β-agonist, isoproterenol (ISO), promote cell adhesion (87.5% cells remaining adherent to the plastic dishes following specific detachment vs. 35.0% in control, P<0.001), while increasing concentrations further engages an additional 36% inhibition of Erk1/2 phosphorylation (p-Erk1/2)-dependent cell proliferation (P<0.01). Isoproterenol dose response on cell adhesion was fitted to a 2-site curve (EC50(1): 16.5±11.5 fM, EC50(2): 4.08±3.09 nM), while ISO significantly inhibited p-Erk1/2 according to a 1-site model (EC50: 0.25±0.13 nM). Using β-AR-selective agonist/antagonists and cAMP analogs/inhibitors, we identified a dosage-dependent signaling in which low ISO concentrations target a β2-AR population localized in raft microdomains and stimulate a Gs/cAMP/Epac/adhesion-signaling module, while higher concentrations engage a concomitant activation of another β2-AR population outside rafts and inhibit the proliferation by a Gs/cAMP/PKA-dependent signaling module. Our data provide a new molecular basis for the dose-dependent switch of β-AR signaling. This study also sheds light on a new cAMP pathway core mechanism with a single receptor triggering dual cAMP signaling controlled by PKA or Epac but with different cellular outputs.
Nonlinear dynamics of multi-omics profiles during human aging.
Shen X, Wang C, Zhou X, Zhou W, Hornburg D, Wu S Nat Aging. 2024; 4(11):1619-1634.
PMID: 39143318 PMC: 11564093. DOI: 10.1038/s43587-024-00692-2.
Silva D, Quintas C, Goncalves J, Fresco P Cells. 2024; 13(3.
PMID: 38334654 PMC: 10854540. DOI: 10.3390/cells13030262.
Signalling of Adrenoceptors: Canonical Pathways and New Paradigms.
Mastos C, Xu X, Keen A, Halls M Handb Exp Pharmacol. 2024; 285:147-184.
PMID: 38227198 DOI: 10.1007/164_2023_704.
Ayama-Canden S, Tondo R, Pineros Leyton M, Ninane N, Demazy C, Dieu M Cell Commun Signal. 2023; 21(1):301.
PMID: 37904233 PMC: 10614342. DOI: 10.1186/s12964-023-01340-9.
Jablonski M, Rodriguez M, Rivero E, Bruque C, Vanzulli S, Bruzzone A Cancer Chemother Pharmacol. 2023; 92(6):485-499.
PMID: 37725114 DOI: 10.1007/s00280-023-04586-9.